Search Patents
  • METHODS, COMPOSITIONS, AND PROPHYLACTICS FOR TREATING, AMELIORATING, OR PREVENTING CORONAVIRUS DISEASE (COVID-19)
    Publication number: 20230235308
    Abstract: Disclosed are the methods and compositions for treating, ameliorating, or preventing COVID-19 or conditions associated with SARS-CoV-2 infection, and, also for reversing the damage caused by SARS-CoV-2 infection. Pharmaceutically acceptable compositions including spike protein binding partners, and optionally personal protective equipment included spike protein binding partners, are also disclosed.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 27, 2023
    Inventors: Matthew Pincus, Steven Evans, Fred Friedman
  • PAN-CORONAVIRUS VACCINE COMPOSITIONS
    Publication number: 20230226173
    Abstract: Pan-coronavirus recombinant vaccine compositions featuring whole proteins or sequences of proteins encompassing all mutations in variants of human and animal Coronaviruses (e.g., 36 mutations in spike protein) or a combination of mutated B cell epitopes, mutated combination of B cell epitopes, mutated CD4+ T cell epitopes, and mutated CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The mutated epitopes may comprise one or more mutations. The present invention also describes using several immuno-informatics and sequence alignment approaches to identify several human B cell, CD4+ and CD8+ T cell epitopes that are highly mutated. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of human and animal Coronaviruses mutations.
    Type: Application
    Filed: October 13, 2022
    Publication date: July 20, 2023
    Inventor: Lbachir BenMohamed
  • IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
    Publication number: 20220323574
    Abstract: Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe Acute Respiratory Syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.
    Type: Application
    Filed: June 1, 2022
    Publication date: October 13, 2022
    Inventor: MICHAEL WAN CHO
  • GENETICALLY ENGINEERED DENDRITIC CELLS TO ACTIVATE PROTEIN SPECIFIC T CELLS FOR THE TREATMENT OF VIRAL AND OTHER PATHOGENIC INFECTIONS
    Publication number: 20230383255
    Abstract: Provided are genetically engineered DC probes/epitopes that are able to stimulate high numbers of a pathogenic or viral, or degenerative protein (such as the functional spike (Sp), membrane (M), and nucleocapsid (N) protein and amyloid beta and tau protein) and produce protein-specific CD4+ and CD8+ T cells ex vivo, which can then be adaptively administered to patients to treat a variety of pathogenic infections, degenerative disorder, including viral infections.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 30, 2023
    Inventors: Aynun N. Begum, Alexander V. Michkov
  • SARS-COV2 CORONAVIRUS RECONSTITUTED RBM AND USES THEREOF
    Publication number: 20230321218
    Abstract: The present invention relates to vaccines and therapeutic compositions targeted at coronaviruses, specifically, the Severe Acute Respiratory Syndrome coronavirus 2 (SARS CoV2). More specifically, the invention provides reconstituted Receptor Binding Motif (RBM) of a Spike protein of the SARS CoV2, Receptor Binding domains (RBDs), and spike proteins comprising the reconstituted RBMs or ?-linkers, compositions, vaccines, therapeutic and diagnostic methods and uses thereof.
    Type: Application
    Filed: April 7, 2021
    Publication date: October 12, 2023
    Inventor: Jonathan M. GERSHONI
  • PRODRUGS, ANALOGS OR DERIVATIVES OF KAEMPFEROL AS ANTIVIRAL AGENTS
    Publication number: 20230064951
    Abstract: The present invention relates to compounds which can inhibit host cell ACE2 receptor, viral spike S protein, Spike protein-ACE2 receptor interface, RNA-dependent RNA polymerase (RdRp), helicase and exoribonuclease activity. Particularly the invention relates to kaempferol analogs, derivatives and prodrugs as antiviral agents specific to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or SARS-CoV-2 and SARS (Severe, acute respiratory syndrome coronavirus).
    Type: Application
    Filed: August 18, 2022
    Publication date: March 2, 2023
    Inventors: Parul P. Lakhlani, Parthasarathy Krishnan
  • SARS-CoV-2 BIOSENSOR UTILIZING A PHOSPHATASE REPORTER
    Publication number: 20230266267
    Abstract: A biosensor capable of detecting both the SARS-CoV-2 S1 spike protein antigen and the SARS-CoV-2 spike protein IgG antibody is disclosed. In various embodiments, the biosensor is configured with an array of solution-gated nanoribbon FETs, wherein each nanoribbon comprises indium oxide (In2O3). In various aspects, the biosensor is fabricated using a scalable and cost-efficient lithography-free process comprising shadow masking.
    Type: Application
    Filed: February 22, 2023
    Publication date: August 24, 2023
    Inventors: Moh Amer, Mingrui Chen, Chongwu Zhou
  • POLYPEPTIDES FOR DETECTION AND TREATMENT OF SARS-COV-2
    Publication number: 20240059760
    Abstract: Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 22, 2024
    Applicant: The University of Chicago
    Inventors: Anthony KOSSIAKOFF, Tomasz SLEZAK
  • Immunogenic and vaccine compositions against SARS-CoV-2
    Patent number: 11376320
    Abstract: Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: July 5, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventor: Michael Wan Cho
  • IMMUNOGENIC COMPOSITION COMPRISING AN ANTIGENIC MOIETY AND A LIPOSOMAL FORMULATION, METHOD OF PRODUCING THE COMPOSITION, THE COMPOSITION FOR USE AS A MEDICAMENT, IN PARTICULAR FOR USE AS A VACCINE
    Publication number: 20230181711
    Abstract: The present invention concerns an immunogenic composition comprising (a) an antigenic moiety, preferably an antigenic moiety being or comprising an amino acid sequence corresponding to a surface protein domain of SARS-CoV-2 virus; and (b) a liposomal formulation as an adjuvant. More specifically, the antigenic moiety preferably is either the receptor binding domain RBD of Spike protein S of SARS-CoV-2 virus, or the HR domain of S2 subunit of spike protein S of SARS-CoV-2 virus; or an immunogenic fragment thereof. The invention further relates to a method of producing an immunogenic composition and the use of such composition as a medicament.
    Type: Application
    Filed: April 7, 2021
    Publication date: June 15, 2023
    Inventors: Stéfan Jonathan HALBHERR, Camille PEITSCH, Diego VON WERDT
  • ANTIBODIES
    Publication number: 20220275059
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.
    Type: Application
    Filed: February 20, 2020
    Publication date: September 1, 2022
    Inventors: Franklin Gerardus GROSVELD, Marinus Johannes VAN HAPEREN, Dubravka DRABEK, Berend Jan BOSCH, Ivy WIDJAJA, Chunyan WANG, Brenda VAN DIEREN, Wentao LI, Frank J.M. VAN KUPPEVELD, Bart L. HAAGMANS, Nisreen M.A. OKBA
  • PRODRUGS, ANALOGS OR DERIVATIVES OF ANTHOCYANIDIN AS ANTIVIRAL AGENTS
    Publication number: 20220411409
    Abstract: The present invention relates to compounds which can inhibit host cell ACE2 receptor, viral spike S protein, Spike protein-ACE2 receptor interface, RNA-dependent RNA polymerase (RdRp), helicase and exoribonuclease activity. Particularly the invention relates to anthocyanidin analogs, derivatives and prodrugs as antiviral agents specific to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or SARS-CoV-2 and SARS (Severe acute respiratory syndrome coronavirus).
    Type: Application
    Filed: June 15, 2022
    Publication date: December 29, 2022
    Inventors: Parul P. Lakhlani, Parthasarathy Krishnan
  • IMMUNOASSAY FOR SARS-COV-2 NEUTRALIZING ANTIBODIES AND MATERIALS THEREFOR
    Publication number: 20220018838
    Abstract: The present invention relates to the development of novel immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples. Novel multiplex and singleplex immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples are also provided.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 20, 2022
    Inventors: QIAN GAO, RAVI KAUL, SHUXIA ZHOU, ROGER P. WALKER
  • SARS-CoV-2 mRNA Vaccine and Preparation Method and Use Thereof
    Publication number: 20240075126
    Abstract: Provided is a SARS-CoV-2 mRNA vaccine, and the preparation method and use thereof. The present invention provides an mRNA molecule capable of encoding a target polypeptide, wherein the target polypeptide comprises an NTD-RBD natural domain in the Spike (S) protein of SARS-CoV-2, and wherein the NTD-RBD natural domain comprises an NTD fragment and an RBD fragment, the NTD fragment and the RBD fragment being linked together via a natural amino acid sequence derived from the S protein as a linker. The present invention provides an mRNA encoding a NTD-RBD natural domain in the Spike protein of SARS-CoV-2, which achieves an immune effect against SARS-CoV-2 mutant strains and is widely applicable.
    Type: Application
    Filed: April 29, 2022
    Publication date: March 7, 2024
    Inventor: Yong HU
  • APTAMERS AGAINST SARS-COV-2
    Publication number: 20230228751
    Abstract: The invention relates to one or more aptamers isolated against the SARS-CoV-2 spike protein and methods of using the same. Certain embodiments of the invention relate to methods of detecting the presence, absence or amount of SARS-CoV-2 in a sample using the one or more aptamers described herein. In certain embodiments, the invention relates to one or more aptamers that are capable of specifically binding to SARS-CoV-2 proteins, including aptamers that are capable of specifically binding to the S1 subunit (including the receptor binding domain (RBD)) and/or the S2 subunit within their native conformation as part of the SARS-CoV-2 spike protein in its trimeric form or as separate monomers.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Arron TOLLEY, David BUNKA, Edward BARNES, Banushan BALANSETHUPATHY, Harriet FLYNN, Janice ROBOTTOM, Laura MILBURN, Phoebe O'HARA, Joe REED
  • EXPRESSION OF PEDV SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME
    Publication number: 20200080101
    Abstract: A plant produced vaccine for Porcine Epidemic Diarrhea Virus (PEDV) is provided where the Spike protein of the virus is expressed in a plant by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleoic acid encoding the Spike protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. The plant expresses the S1 polypeptide at levels of at least 10 mg/kg of seed of said plant. When orally administered to an animal, a protective response is observed including a serum antibody response.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 12, 2020
    Inventors: John Howard, Erin Egelkrout, Celine Hayden
  • MODIFIED POLYPEPTIDES WITH IMPROVED PROPERTIES
    Publication number: 20240033343
    Abstract: This disclosure relates generally to modified SARS-CoV-2 spike polypeptides. More particularly, the present disclosure relates to modified SARS-CoV-2 spike proteins with improved properties, to chimeric polypeptides comprising these modified proteins, and to complexes comprising the chimeric polypeptides. The present disclosure also relates to the use of these modified polypeptides, chimeric polypeptides and complexes in compositions and methods for eliciting an immune response to ACE2-interacting coronaviruses, including SARS-CoV-2, and/or for treating or inhibiting the development of ACE2-interacting coronaviruses infections.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 1, 2024
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: Keith CHAPPELL, Paul YOUNG, Daniel WATTERSON
  • SARS-CoV-2 mRNA vaccine and preparation method and use thereof
    Patent number: 11931410
    Abstract: Provided is a SARS-CoV-2 mRNA vaccine, and the preparation method and use thereof. The present invention provides an mRNA molecule capable of encoding a target polypeptide, wherein the target polypeptide comprises an NTD-RBD natural domain in the Spike (S) protein of SARS-CoV-2, and wherein the NTD-RBD natural domain comprises an NTD fragment and an RBD fragment, the NTD fragment and the RBD fragment being linked together via a natural amino acid sequence derived from the S protein as a linker. The present invention provides an mRNA encoding a NTD-RBD natural domain in the Spike protein of SARS-CoV-2, which achieves an immune effect against SARS-CoV-2 mutant strains and is widely applicable.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 19, 2024
    Assignee: SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD.
    Inventor: Yong Hu
  • Systemic delivery of non-viral vector expressing SARS viral genomic vaccine
    Publication number: 20050025788
    Abstract: The present invention relates to a non-viral vector for SARS Viral Genomic Vaccine. The present invention also relates to a non-targeted lipoplex or PEGylated lipoplex formulation for accumulating SARS spike genome in the lung to that results in expression of SARS spike protein.
    Type: Application
    Filed: June 4, 2004
    Publication date: February 3, 2005
    Inventor: George Chou
  • Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
    Patent number: 11740240
    Abstract: The present invention relates to the development of novel immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples. Novel multiplex and singleplex immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples are also provided.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: August 29, 2023
    Assignee: BIO-RAD LABORATORIES, INC.
    Inventors: Qian Gao, Ravi Kaul, Shuxia Zhou, Roger P. Walker
Narrow Results

Filter by US Classification